Hendrik Neubert1, Jeremy Gale, David Muirhead. 1. Pharmacokinetics Dynamics & Metabolism and Biotherapeutics & Translational Research, Pfizer Limited, Kent, UK. hendrik.neubert@pfizer.com
Abstract
BACKGROUND: Detection limit challenges associated with measuring low-abundance protein biomarkers can be addressed with hybrid immunoaffinity-mass spectrometric assays, such as antipeptide antibody capture followed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Popular assay formats use magnetic bead-based immunoaffinity enrichment and nanoflow LC-MS/MS or high-flow immunoaffinity chromatography coupled online to conventional LC-MS/MS. As a proof of principle, we describe a novel online immunoaffinity LC-MS/MS configuration that combines high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS. METHODS: We configured and validated an assay for the measurement of total pepsin/pepsinogen from human saliva that uses a pepsinogen standard. Saliva was heat-inactivated to quench residual enzymatic activity and then digested with endoproteinase AspN. Online immunoaffinity enrichment using an antipeptide antibody directed against the pepsin C-terminal sequence, DRANNQVGLAPVA, was linked to nanoflow liquid chromatography and selected reaction monitoring mass spectrometry. We used the assay to measure pepsin/pepsinogen concentrations in human saliva from presumed healthy volunteers. RESULTS: Heat inactivation at 100 degrees C for 25 min stabilized the target peptide. The final assay had <15% interassay relative error and <15% interassay CV across a range of 4.08-2980 pmol/L human pepsinogen (0.165-120 microg/L). Low but quantifiable signals were observed in some samples from presumed normal healthy volunteers ranging from 4.3 to 16.6 pmol/L (0.17-0.67 microg/L) total salivary pepsin/pepsinogen. CONCLUSIONS: This assay approach provides a high-sensitivity platform for protein bioanalysis in the low picomolar range. It bears the potential to deliver additional data on the salivary occurrence of pepsin/pepsinogen with greater confidence than previously.
BACKGROUND: Detection limit challenges associated with measuring low-abundance protein biomarkers can be addressed with hybrid immunoaffinity-mass spectrometric assays, such as antipeptide antibody capture followed by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Popular assay formats use magnetic bead-based immunoaffinity enrichment and nanoflow LC-MS/MS or high-flow immunoaffinity chromatography coupled online to conventional LC-MS/MS. As a proof of principle, we describe a novel online immunoaffinity LC-MS/MS configuration that combines high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS. METHODS: We configured and validated an assay for the measurement of total pepsin/pepsinogen from human saliva that uses a pepsinogen standard. Saliva was heat-inactivated to quench residual enzymatic activity and then digested with endoproteinase AspN. Online immunoaffinity enrichment using an antipeptide antibody directed against the pepsin C-terminal sequence, DRANNQVGLAPVA, was linked to nanoflow liquid chromatography and selected reaction monitoring mass spectrometry. We used the assay to measure pepsin/pepsinogen concentrations in human saliva from presumed healthy volunteers. RESULTS: Heat inactivation at 100 degrees C for 25 min stabilized the target peptide. The final assay had <15% interassay relative error and <15% interassay CV across a range of 4.08-2980 pmol/L human pepsinogen (0.165-120 microg/L). Low but quantifiable signals were observed in some samples from presumed normal healthy volunteers ranging from 4.3 to 16.6 pmol/L (0.17-0.67 microg/L) total salivary pepsin/pepsinogen. CONCLUSIONS: This assay approach provides a high-sensitivity platform for protein bioanalysis in the low picomolar range. It bears the potential to deliver additional data on the salivary occurrence of pepsin/pepsinogen with greater confidence than previously.
Authors: Eric Kuhn; Jeffrey R Whiteaker; D R Mani; Angela M Jackson; Lei Zhao; Matthew E Pope; Derek Smith; Keith D Rivera; N Leigh Anderson; Steven J Skates; Terry W Pearson; Amanda G Paulovich; Steven A Carr Journal: Mol Cell Proteomics Date: 2011-12-22 Impact factor: 5.911
Authors: Jeffrey R Whiteaker; Lei Zhao; Susan E Abbatiello; Michael Burgess; Eric Kuhn; ChenWei Lin; Matthew E Pope; Morteza Razavi; N Leigh Anderson; Terry W Pearson; Steven A Carr; Amanda G Paulovich Journal: Mol Cell Proteomics Date: 2011-01-18 Impact factor: 5.911
Authors: John P Dekker; Anthony F Suffredini; Honghui Wang; Jeffrey R Strich; Steven K Drake; Yong Chen; Jung-Ho Youn; Avi Z Rosenberg; Marjan Gucek Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Weixun Wang; Bernard K Choi; Wenyu Li; Zhege Lao; Anita Y H Lee; Sandra C Souza; Nathan A Yates; Timothy Kowalski; Alessandro Pocai; Lucinda H Cohen Journal: J Am Soc Mass Spectrom Date: 2014-02-06 Impact factor: 3.109
Authors: Firas H Kobeissy; Basri Gulbakan; Ali Alawieh; Pierre Karam; Zhiqun Zhang; Joy D Guingab-Cagmat; Stefania Mondello; Weihong Tan; John Anagli; Kevin Wang Journal: OMICS Date: 2014-01-10